Global Capillary Blood Collection Devices Market Size, Trend & Opportunity Analysis Report, by Material (Plastic, Glass, Stainless Steel), and Forecast, 2024–2035
Description
Market Definition and Introduction
The global capillary blood collection devices market, valued at USD 2.13 billion in 2024, is projected to reach USD 5.39 billion by 2035, growing at a robust CAGR of 8.8% during the forecast period (2024–2035). A wave of changes being witnessed by the sector is pointing towards this accelerated trend toward minimally invasive diagnostics and a shift toward testing at the point of care. In modern diagnostics, capillary blood collection emerges as a critical element that is offering access to sample collection on the run for glucose monitoring, newborn screening, or infectious disease testing while minimising discomfort to patients significantly when compared with traditional venipuncture.
Market trajectories are modelled by three emerging trends, such as the spread of the global diabetes epidemic, which maximally confines glucose measurement to time, as well as the emergence of decentralised testing within retail clinics and pharmacies. The penultimate condition is the improvement in techniques of microsampling. Plasticised application devices dominate the sector by cost-effectiveness and disposal purposes; on the other hand, lancets made of stainless steel bring in strong demand, specifically in fields where sharpness and durability are valued. The importance of capillary sampling is further accentuated by COVID-19, which facilitates the unfreezing of home test kits for decentralised models to health care providers and patients.
The collection of samples presents various challenges for the industry, including variability in sample quality and the need for collection protocols across different patient populations. The leaders in the market have made various responses to address these issues by introducing innovative product designs that feature adjustable penetration depth and integrated safety mechanisms. The next frontier in blood collection, complemented by real-time data transmission to electronic health records, a development that could revolutionise the management of chronic diseases and clinical trial monitoring, is the advent of smart lancets fitted with digital connectivity.
Recent Developments in the Industry
BD Launches Next-Gen Safety Lancet with Pain Reduction Technology
In March 2024, Becton Dickinson came up with its Microtainer® Painless lancet, which utilises an in-house microgeometry technology to lower nerve-stimulation by 40% as against that of traditional designs. The device, FDA-cleared, was specifically produced for pediatric and geriatric populations, with clinical trials showing much-improved patient compliance concerning frequent testing regimens.
Greiner Bio-One Launches Integrated Collection of Capillary Sample
In January 2024, Greiner Bio-One launched its VACUETTE® CBC System, which integrates capillary tube collection with a proprietary chemistry that stabilises the sample and prevents its degradation during transport. This closed-system design has established a 30% improvement in sample accuracy related to hematocrit measurement for validation. It particularly benefits rural health care settings that have limited laboratory infrastructures.
Thermo Fisher Scientific Acquires the Microsampling Specialist
Thermo Fisher Scientific internally acquired Hemaxis Diagnostics for $320 million in November 2023 to get patented volumetric absorptive microsampling (VAMS) technology. Strategically, this positions Thermo Fisher as a leader in the remote collection of samples necessary for clinical trials since this technology allows stable blood spots at ambient temperatures for 30 days.
The Terumo Partners with a Digital Health Platform for Smart Lancet Integration
Terumo Corporation made its announcement of entering into a collaboration with HealthTrackRx in July 2024 for the manufacture of Bluetooth-enabled collection devices that automatically log into patient monitoring systems after collection and would provide improved tracking of medication adherence in anticoagulant therapy patients. Pilot programs reveal a 25% improvement rate in compliance.
Market Dynamics
The pandemic situation for diabetes is resulting in an unprecedented demand for glucose testing devices globally.
By 2045, diabetes is predicted to afflict 700 million people, thus continuing its onslaught on capillary collection solutions. BD's recent market analysis outlined that 18% more lancets are being used each year in emerging markets, with emphasis laid on the pivotal role that cost-efficient monitoring solutions will play in dealing with the disease burden. Furthermore, continuous glucose monitoring (CGM) systems will need capillary confirmation for a while yet, thus preserving a constant demand even as sensor technology continues to advance.
Decentralised Testing: A Game-Changer for Application Extension
These retail health clinics and pharmacy-based testing pursuits have created a 32% annual growth of capillary collection apparatuses for lipid panels and HbA1c testing. SARSTEDT S-Monovette system, in particular, has become increasingly popular in pharmacies across Europe, whereby trained personnel obtain lab-quality samples without venipuncture-related apparatus. As a result, hospital visits for routine monitoring are curtailed, while offering testing to the so-called underserved populations.
Microsampling Breakthroughs Convert Clinical Trials Economics
VAMS is disrupting conventional clinical trial operations by enabling remote patient monitoring. Thermo Fisher's Mitra devices cut the costs of Phase III trials by 40% through the avoidance of site visits for sample collection, especially valuable in pediatric and rare disease studies where blood volumes are limited.
Regulatory Harmonization Creates Standardization Obstacles
Discrepancy in standards applicable in the international market of lancet manufacturing and safety features is becoming more complicated by virtue of their diverging nature. The European Union recently requires a higher compliance cost of about 25% for manufacturers following the revised IVDR classification for capillary devices. The FDA's 510k pathway, on the other hand, remains the most attractive avenue for market entry. Such regulatory fragmentation induces the option for companies to create modular platforms for products adaptable to the regional requirements.
Material Science Innovations Solve Concerns about Sample Quality
With the development of advanced polymer formulations, limitations of plastic devices are gradually being overcome; Medline's Ultrasafe Plus lancets yield samples that are comparable to steel ones in quality. This advancement is expected to have a profound effect on point-of-care haemoglobin testing, with earlier variants of plastic devices displaying 15% greater variability in rural field trials.
Attractive Opportunities in the Market
Smart Lancet Tech: IoT-enabled devices for digital health integration
Neonatal Screening: Specialised devices for premature infant testing
Home Diagnostics: Consumer-friendly collection kits for direct-to-consumer testing
Microsampling: Devices enabling remote clinical trial participation
Eco-Design: Recyclable and biodegradable material alternatives
Pain Reduction: Innovative geometries minimise nerve stimulation
Emerging Markets: Cost-optimised solutions for resource-limited settings
Haematology Apps: Devices optimised for complete blood count testing
Safety Features: Advanced engineering preventing needlestick injuries
Customisation: Patient-specific devices for unique clinical needs
Report Segmentation
By Material: Plastic, Glass, Stainless Steel
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players
Becton, Dickinson and Company (BD), Greiner Bio-One International GmbH, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., Terumo Corporation, Medline Industries, LP, Improve Medical, Nipro Corporation, Owen Mumford Ltd, and Cardinal Health.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293
Dominating Segments
Plastic Segment Commands 62% Market Share Through Cost and Safety Advantages.
The plastic capillary devices have some real strength corresponding to their disposability and cost-effectiveness, and with evolving material properties, they are now rivalling glass in terms of sample quality. The BD Microtainer® product is a good case in point, wherein advanced polymer formulations enable the same perforation from a 30G needle to be rendered at 40% lower costs as compared to glass. The segment is further gaining traction from increasing acceptance in diabetes management, where the patient has to alter the lancet every day, building a strong demand for economical and single-use solutions.
Stainless Steel Maintains Niche Dominance in Specialised Applications
Stainless steel lancets are said to occupy a critical position in applications needing ultra-precise penetration depth control, although they occupy only 28% of the market. Owen Mumford's Unistik® range proves steel's continued relevance in neonatal screening and coagulation testing, where sample quality consistency is key. Steel alloy composition advances have recently turned sharper blades as much as 50% longer-lasting, thus attenuating concerns around multiple-use dullness.
Glass Capillary Tubes Find Renewed Utility in Microsampling Innovations
The glass capillary products hold only a 10% market share, but the segment is now getting a second wind through microsampling applications. Thermo Fisher's collaboration with Neoteryx has resulted in the arrival of glass-based VAMS devices that keep samples intact for weeks and have changed the landscape for remote monitoring of clinical trials. The inert properties of the material leave it as the only choice for trace element analysis, since any other plastic alternative could introduce measurement artefacts.
Regional Insights
North America: Evolved Diabetes Care System and 38% Market Share
The U.S. takes the lead in the regional demand due to the high prevalence of diabetes and the increased role of at-home testing; BD and Cardinal Health are two companies that have rolled out integrated collection systems, combining lancets with digital health platforms to provide seamless data flow from patient to provider. The strict safety regulations in the region continue to drive innovation in needlestick prevention technology.
Europe's Strong Diagnostics Sector Driving 29% Revenue Contribution.
Nearby Germany and France lead in adoption in Europe, with SARSTEDT and Greiner Bio-One interested in specialised devices for decentralised testing networks. The transition to safety-engineered devices has been expedited due to the EU focus on occupational safety, which now dominates the regional market by 85%. The new IVDR reforms are raising the quality standards for capillary collection products to even higher levels.
Asia-Pacific Emerges Fastest-Growing Market at 13.2% CAGR.
The exploding demand is being driven by an expanding middle class and increasing diabetes burden in China and India. Terumo and Nipro are localising production for cost-optimised solutions, with Indian manufacturers achieving a 30% price advantage. Government screening programs for neonatal disorders and hemoglobinopathies are creating new volume opportunities across the region.
Core Strategic Questions Answered in This Report
What is the expected growth trajectory of the capillary blood collection devices market from 2024 to 2035?
The market will expand from USD 2.13 billion in 2024 to USD 5.39 billion by 2035, growing at an 8.8% CAGR, driven by diabetes management needs and decentralised testing adoption.
Which key factors are fuelling the growth of the capillary blood collection devices market?
Global diabetes epidemic requiring frequent monitoring
Shift toward decentralised and point-of-care testing
Advancements in microsampling technologies
Growing preference for minimally invasive procedures
Expansion of home-based diagnostic testing
Increasing neonatal screening programs worldwide
What are the primary challenges hindering the growth of the capillary blood collection devices market?
Sample quality variability across patient populations
Lack of standardised collection protocols
Regulatory divergence across markets
Price sensitivity in emerging economies
Competition from non-invasive monitoring technologies
Environmental concerns about device disposability
Which regions currently lead the capillary blood collection devices market in terms of market share?
North America leads with 38% share (U.S. diabetes care), followed by Europe at 29% (stringent diagnostics standards), and Asia-Pacific at 25% (rapid healthcare expansion).
What emerging opportunities are anticipated in the capillary blood collection devices market?
Digital health-integrated smart lancets
Microsampling for decentralised clinical trials
Specialised neonatal collection devices
Sustainable material innovations
Pain-reduction technologies
Emerging market screening programs
Haematology testing applications
Occupational safety advancements
Direct-to-consumer testing kits
Customised devices for unique populations
Key Benefits for Stakeholders
The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
The global capillary blood collection devices market, valued at USD 2.13 billion in 2024, is projected to reach USD 5.39 billion by 2035, growing at a robust CAGR of 8.8% during the forecast period (2024–2035). A wave of changes being witnessed by the sector is pointing towards this accelerated trend toward minimally invasive diagnostics and a shift toward testing at the point of care. In modern diagnostics, capillary blood collection emerges as a critical element that is offering access to sample collection on the run for glucose monitoring, newborn screening, or infectious disease testing while minimising discomfort to patients significantly when compared with traditional venipuncture.
Market trajectories are modelled by three emerging trends, such as the spread of the global diabetes epidemic, which maximally confines glucose measurement to time, as well as the emergence of decentralised testing within retail clinics and pharmacies. The penultimate condition is the improvement in techniques of microsampling. Plasticised application devices dominate the sector by cost-effectiveness and disposal purposes; on the other hand, lancets made of stainless steel bring in strong demand, specifically in fields where sharpness and durability are valued. The importance of capillary sampling is further accentuated by COVID-19, which facilitates the unfreezing of home test kits for decentralised models to health care providers and patients.
The collection of samples presents various challenges for the industry, including variability in sample quality and the need for collection protocols across different patient populations. The leaders in the market have made various responses to address these issues by introducing innovative product designs that feature adjustable penetration depth and integrated safety mechanisms. The next frontier in blood collection, complemented by real-time data transmission to electronic health records, a development that could revolutionise the management of chronic diseases and clinical trial monitoring, is the advent of smart lancets fitted with digital connectivity.
Recent Developments in the Industry
BD Launches Next-Gen Safety Lancet with Pain Reduction Technology
In March 2024, Becton Dickinson came up with its Microtainer® Painless lancet, which utilises an in-house microgeometry technology to lower nerve-stimulation by 40% as against that of traditional designs. The device, FDA-cleared, was specifically produced for pediatric and geriatric populations, with clinical trials showing much-improved patient compliance concerning frequent testing regimens.
Greiner Bio-One Launches Integrated Collection of Capillary Sample
In January 2024, Greiner Bio-One launched its VACUETTE® CBC System, which integrates capillary tube collection with a proprietary chemistry that stabilises the sample and prevents its degradation during transport. This closed-system design has established a 30% improvement in sample accuracy related to hematocrit measurement for validation. It particularly benefits rural health care settings that have limited laboratory infrastructures.
Thermo Fisher Scientific Acquires the Microsampling Specialist
Thermo Fisher Scientific internally acquired Hemaxis Diagnostics for $320 million in November 2023 to get patented volumetric absorptive microsampling (VAMS) technology. Strategically, this positions Thermo Fisher as a leader in the remote collection of samples necessary for clinical trials since this technology allows stable blood spots at ambient temperatures for 30 days.
The Terumo Partners with a Digital Health Platform for Smart Lancet Integration
Terumo Corporation made its announcement of entering into a collaboration with HealthTrackRx in July 2024 for the manufacture of Bluetooth-enabled collection devices that automatically log into patient monitoring systems after collection and would provide improved tracking of medication adherence in anticoagulant therapy patients. Pilot programs reveal a 25% improvement rate in compliance.
Market Dynamics
The pandemic situation for diabetes is resulting in an unprecedented demand for glucose testing devices globally.
By 2045, diabetes is predicted to afflict 700 million people, thus continuing its onslaught on capillary collection solutions. BD's recent market analysis outlined that 18% more lancets are being used each year in emerging markets, with emphasis laid on the pivotal role that cost-efficient monitoring solutions will play in dealing with the disease burden. Furthermore, continuous glucose monitoring (CGM) systems will need capillary confirmation for a while yet, thus preserving a constant demand even as sensor technology continues to advance.
Decentralised Testing: A Game-Changer for Application Extension
These retail health clinics and pharmacy-based testing pursuits have created a 32% annual growth of capillary collection apparatuses for lipid panels and HbA1c testing. SARSTEDT S-Monovette system, in particular, has become increasingly popular in pharmacies across Europe, whereby trained personnel obtain lab-quality samples without venipuncture-related apparatus. As a result, hospital visits for routine monitoring are curtailed, while offering testing to the so-called underserved populations.
Microsampling Breakthroughs Convert Clinical Trials Economics
VAMS is disrupting conventional clinical trial operations by enabling remote patient monitoring. Thermo Fisher's Mitra devices cut the costs of Phase III trials by 40% through the avoidance of site visits for sample collection, especially valuable in pediatric and rare disease studies where blood volumes are limited.
Regulatory Harmonization Creates Standardization Obstacles
Discrepancy in standards applicable in the international market of lancet manufacturing and safety features is becoming more complicated by virtue of their diverging nature. The European Union recently requires a higher compliance cost of about 25% for manufacturers following the revised IVDR classification for capillary devices. The FDA's 510k pathway, on the other hand, remains the most attractive avenue for market entry. Such regulatory fragmentation induces the option for companies to create modular platforms for products adaptable to the regional requirements.
Material Science Innovations Solve Concerns about Sample Quality
With the development of advanced polymer formulations, limitations of plastic devices are gradually being overcome; Medline's Ultrasafe Plus lancets yield samples that are comparable to steel ones in quality. This advancement is expected to have a profound effect on point-of-care haemoglobin testing, with earlier variants of plastic devices displaying 15% greater variability in rural field trials.
Attractive Opportunities in the Market
Smart Lancet Tech: IoT-enabled devices for digital health integration
Neonatal Screening: Specialised devices for premature infant testing
Home Diagnostics: Consumer-friendly collection kits for direct-to-consumer testing
Microsampling: Devices enabling remote clinical trial participation
Eco-Design: Recyclable and biodegradable material alternatives
Pain Reduction: Innovative geometries minimise nerve stimulation
Emerging Markets: Cost-optimised solutions for resource-limited settings
Haematology Apps: Devices optimised for complete blood count testing
Safety Features: Advanced engineering preventing needlestick injuries
Customisation: Patient-specific devices for unique clinical needs
Report Segmentation
By Material: Plastic, Glass, Stainless Steel
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players
Becton, Dickinson and Company (BD), Greiner Bio-One International GmbH, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., Terumo Corporation, Medline Industries, LP, Improve Medical, Nipro Corporation, Owen Mumford Ltd, and Cardinal Health.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293
Dominating Segments
Plastic Segment Commands 62% Market Share Through Cost and Safety Advantages.
The plastic capillary devices have some real strength corresponding to their disposability and cost-effectiveness, and with evolving material properties, they are now rivalling glass in terms of sample quality. The BD Microtainer® product is a good case in point, wherein advanced polymer formulations enable the same perforation from a 30G needle to be rendered at 40% lower costs as compared to glass. The segment is further gaining traction from increasing acceptance in diabetes management, where the patient has to alter the lancet every day, building a strong demand for economical and single-use solutions.
Stainless Steel Maintains Niche Dominance in Specialised Applications
Stainless steel lancets are said to occupy a critical position in applications needing ultra-precise penetration depth control, although they occupy only 28% of the market. Owen Mumford's Unistik® range proves steel's continued relevance in neonatal screening and coagulation testing, where sample quality consistency is key. Steel alloy composition advances have recently turned sharper blades as much as 50% longer-lasting, thus attenuating concerns around multiple-use dullness.
Glass Capillary Tubes Find Renewed Utility in Microsampling Innovations
The glass capillary products hold only a 10% market share, but the segment is now getting a second wind through microsampling applications. Thermo Fisher's collaboration with Neoteryx has resulted in the arrival of glass-based VAMS devices that keep samples intact for weeks and have changed the landscape for remote monitoring of clinical trials. The inert properties of the material leave it as the only choice for trace element analysis, since any other plastic alternative could introduce measurement artefacts.
Regional Insights
North America: Evolved Diabetes Care System and 38% Market Share
The U.S. takes the lead in the regional demand due to the high prevalence of diabetes and the increased role of at-home testing; BD and Cardinal Health are two companies that have rolled out integrated collection systems, combining lancets with digital health platforms to provide seamless data flow from patient to provider. The strict safety regulations in the region continue to drive innovation in needlestick prevention technology.
Europe's Strong Diagnostics Sector Driving 29% Revenue Contribution.
Nearby Germany and France lead in adoption in Europe, with SARSTEDT and Greiner Bio-One interested in specialised devices for decentralised testing networks. The transition to safety-engineered devices has been expedited due to the EU focus on occupational safety, which now dominates the regional market by 85%. The new IVDR reforms are raising the quality standards for capillary collection products to even higher levels.
Asia-Pacific Emerges Fastest-Growing Market at 13.2% CAGR.
The exploding demand is being driven by an expanding middle class and increasing diabetes burden in China and India. Terumo and Nipro are localising production for cost-optimised solutions, with Indian manufacturers achieving a 30% price advantage. Government screening programs for neonatal disorders and hemoglobinopathies are creating new volume opportunities across the region.
Core Strategic Questions Answered in This Report
What is the expected growth trajectory of the capillary blood collection devices market from 2024 to 2035?
The market will expand from USD 2.13 billion in 2024 to USD 5.39 billion by 2035, growing at an 8.8% CAGR, driven by diabetes management needs and decentralised testing adoption.
Which key factors are fuelling the growth of the capillary blood collection devices market?
Global diabetes epidemic requiring frequent monitoring
Shift toward decentralised and point-of-care testing
Advancements in microsampling technologies
Growing preference for minimally invasive procedures
Expansion of home-based diagnostic testing
Increasing neonatal screening programs worldwide
What are the primary challenges hindering the growth of the capillary blood collection devices market?
Sample quality variability across patient populations
Lack of standardised collection protocols
Regulatory divergence across markets
Price sensitivity in emerging economies
Competition from non-invasive monitoring technologies
Environmental concerns about device disposability
Which regions currently lead the capillary blood collection devices market in terms of market share?
North America leads with 38% share (U.S. diabetes care), followed by Europe at 29% (stringent diagnostics standards), and Asia-Pacific at 25% (rapid healthcare expansion).
What emerging opportunities are anticipated in the capillary blood collection devices market?
Digital health-integrated smart lancets
Microsampling for decentralised clinical trials
Specialised neonatal collection devices
Sustainable material innovations
Pain-reduction technologies
Emerging market screening programs
Haematology testing applications
Occupational safety advancements
Direct-to-consumer testing kits
Customised devices for unique populations
Key Benefits for Stakeholders
The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Table of Contents
285 Pages
- Chapter 1. Market Snapshot
- 1.1. Market Definition & Report Overview
- 1.2. Market Segmentation
- 1.3. Key Takeaways
- 1.3.1. Top Investment Pockets
- 1.3.2. Top Winning Strategies
- 1.3.3. Market Indicators Analysis
- 1.3.4. Top Impacting Factors
- 1.4. Application Ecosystem Analysis
- 1.4.1. 360’ Analysis
- Chapter 2. Executive Summary
- 2.1. CEO/CXO Standpoint
- 2.2. Strategic Insights
- 2.3. ESG Analysis
- 2.4. Market Attractiveness Analysis (top leader’s point of view on the market)
- 2.5. Key Findings
- Chapter 3. Research Methodology
- 3.1. Research Objective
- 3.2. Supply Side Analysis
- 3.2.1. Primary Research
- 3.2.2. Secondary Research
- 3.3. Demand Side Analysis
- 3.3.1. Primary Research
- 3.3.2. Secondary Research
- 3.4. Forecasting Models
- 3.4.1. Assumptions
- 3.4.2. Forecasts Parameters
- 3.5. Competitive breakdown
- 3.5.1. Market Positioning
- 3.5.2. Competitive Strength
- 3.6. Scope of the Study
- 3.6.1. Research Assumption
- 3.6.2. Inclusion & Exclusion
- 3.6.3. Limitations
- Chapter 4. Industry Landscape
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.2. Porter’s 5 Forces Model
- 4.2.1. Bargaining Power of Buyer
- 4.2.2. Bargaining Power of Supplier
- 4.2.3. Threat of New Entrants
- 4.2.4. Threat of Substitutes
- 4.2.5. Competitive Rivalry
- 4.3. Value Chain Analysis
- 4.4. PESTEL Analysis
- 4.5. Pricing Analysis and Trends
- 4.6. Key growth factors and trends analysis
- 4.7. Market Share Analysis (2024)
- 4.8. Top Winning Strategies (2024)
- 4.9. Trade Data Analysis (Import Export)
- 4.10. Regulatory Guidelines
- 4.11. Historical Data Analysis
- 4.12. Analyst Recommendation & Conclusion
- Chapter 5. Global Capillary Blood Collection Devices Market Size & Forecasts by Material 2024-2035
- 5.1. Market Overview
- 5.1.1. Market Size and Forecast By Material 2024-2035
- 5.2. Plastic
- 5.2.1. Market definition, current market trends, growth factors, and opportunities
- 5.2.2. Market size analysis, by region, 2024-2035
- 5.2.3. Market share analysis, by country, 2024-2035
- 5.3. Glass
- 5.3.1. Market definition, current market trends, growth factors, and opportunities
- 5.3.2. Market size analysis, by region, 2024-2035
- 5.3.3. Market share analysis, by country, 2024-2035
- 5.4. Stainless Steel
- 5.4.1. Market definition, current market trends, growth factors, and opportunities
- 5.4.2. Market size analysis, by region, 2024-2035
- 5.4.3. Market share analysis, by country, 2024-2035
- Chapter 6. Global Capillary Blood Collection Devices Market Size & Forecasts by Region 2024–2035
- 6.1. Regional Overview 2024-2035
- 6.2. Top Leading and Emerging Nations
- 6.3. North America Capillary Blood Collection Devices Market
- 6.3.1. U.S. Capillary Blood Collection Devices Market
- 6.3.1.1. Material breakdown size & forecasts, 2024-2035
- 6.3.2. Canada Capillary Blood Collection Devices Market
- 6.3.2.1. Material breakdown size & forecasts, 2024-2035
- 6.3.3. Mexico Capillary Blood Collection Devices Market
- 6.3.3.1. Material breakdown size & forecasts, 2024-2035
- 6.4. Europe Capillary Blood Collection Devices Market
- 6.4.1. UK Capillary Blood Collection Devices Market
- 6.4.1.1. Material breakdown size & forecasts, 2024-2035
- 6.4.2. Germany Capillary Blood Collection Devices Market
- 6.4.2.1. Material breakdown size & forecasts, 2024-2035
- 6.4.3. France Capillary Blood Collection Devices Market
- 6.4.3.1. Material breakdown size & forecasts, 2024-2035
- 6.4.4. Spain Capillary Blood Collection Devices Market
- 6.4.4.1. Material breakdown size & forecasts, 2024-2035
- 6.4.5. Italy Capillary Blood Collection Devices Market
- 6.4.5.1. Material breakdown size & forecasts, 2024-2035
- 6.4.6. Rest of Europe Capillary Blood Collection Devices Market
- 6.4.6.1. Material breakdown size & forecasts, 2024-2035
- 6.5. Asia Pacific Capillary Blood Collection Devices Market
- 6.5.1. China Capillary Blood Collection Devices Market
- 6.5.1.1. Material breakdown size & forecasts, 2024-2035
- 6.5.2. India Capillary Blood Collection Devices Market
- 6.5.2.1. Material breakdown size & forecasts, 2024-2035
- 6.5.3. Japan Capillary Blood Collection Devices Market
- 6.5.3.1. Material breakdown size & forecasts, 2024-2035
- 6.5.4. Australia Capillary Blood Collection Devices Market
- 6.5.4.1. Material breakdown size & forecasts, 2024-2035
- 6.5.5. South Korea Capillary Blood Collection Devices Market
- 6.5.5.1. Material breakdown size & forecasts, 2024-2035
- 6.5.6. Rest of APAC Capillary Blood Collection Devices Market
- 6.5.6.1. Material breakdown size & forecasts, 2024-2035
- 6.6. LAMEA Capillary Blood Collection Devices Market
- 6.6.1. Brazil Capillary Blood Collection Devices Market
- 6.6.1.1. Material breakdown size & forecasts, 2024-2035
- 6.6.2. Argentina Capillary Blood Collection Devices Market
- 6.6.2.1. Material breakdown size & forecasts, 2024-2035
- 6.6.3. UAE Capillary Blood Collection Devices Market
- 6.6.3.1. Material breakdown size & forecasts, 2024-2035
- 6.6.4. Saudi Arabia (KSA Capillary Blood Collection Devices Market
- 6.6.4.1. Material breakdown size & forecasts, 2024-2035
- 6.6.5. Africa Capillary Blood Collection Devices Market
- 6.6.5.1. Material breakdown size & forecasts, 2024-2035
- 6.6.6. Rest of LAMEA Capillary Blood Collection Devices Market
- 6.6.6.1. Material breakdown size & forecasts, 2024-2035
- Chapter 7. Company Profiles
- 7.1. Top Market Strategies
- 7.2. Company Profiles
- 7.2.1. Becton, Dickinson and Company (BD)
- 7.2.1.1. Company Overview
- 7.2.1.2. Key Executives
- 7.2.1.3. Company Snapshot
- 7.2.1.4. Financial Performance (Subject to Data Availability)
- 7.2.1.5. Product/Services Port
- 7.2.1.6. Recent Development
- 7.2.1.7. Market Strategies
- 7.2.1.8. SWOT Analysis
- 7.2.2. Greiner Bio-One International GmbH
- 7.2.3. SARSTEDT AG & Co. KG
- 7.2.4. Thermo Fisher Scientific Inc.
- 7.2.5. Terumo Corporation
- 7.2.6. Medline Industries, LP
- 7.2.7. Improve Medical
- 7.2.8. Nipro Corporation
- 7.2.9. Owen Mumford Ltd
- 7.2.10. Cardinal Health
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


